Takeover : pool your guesses !, page-7

I think it will most likely be Edwards but there are many possible suitors and interested parties. Hopefully a bit of competition for a generational asset helps achieve a great result. However, I obviously don’t know when it will happen or for how much. But I believe despite Redants best wishes it will 100% happen.

It really depends on how far down the commercialisation path we get independently. This is THE key.

Pre FDA approval and post FDA approval and first sales are worlds apart in value terms. So it’s too hard to peg a value.

If I had to guess and speculate for fun I suspect it may happen in the next 18 months but if it was longer than that I think we would realise significantly more value.

The next 12 months to use a “Chillyism” will be transformational for AVR. Just so much news flow to come.

Some of the big ones:

Next 5 patients (Georgia) imminent.
FDA study approval
FDA Breakthrough Device Designation
Further data on ground breaking attributes that further differentiate DurAVR that will come after further proof is received (perfect Laminar flow etc etc).
Nasdaq listing (will be big, US investors unlike AUS investors understand the TAVR market and TAVR companies)
The start of CE mark European registration studies
Various innovation awards and conference podium presentations by our Ad Board and other respected Doctos
Publication of peer reviewed studies in well known cardiovascular medical journals.

And who knows what else will come up but that’s a lot of pivotal news flow.

DYOR and Not advice.